Dendritic Cell Control of Intestinal T Cell Responses

树突状细胞控制肠道 T 细胞反应

基本信息

项目摘要

DESCRIPTION (provided by applicant): Mucosal surfaces such as the intestinal epithelium provide a complex challenge to the immune system, as they must maintain effective immunity against potential pathogen attack while also tolerating commensal microorganisms and dietary antigens. The balance between tolerance and immunity is mediated in large part by the specialized T cell populations, regulatory T cells (Tregs) and Th17 cells. Disruption of the balance between these subsets has been heavily implicated in causing colitis through studies in both mice and humans. Furthermore, Th17 cells are emerging as contributors to many other inflammatory and autoimmune disorders. Understanding how Th17 responses are initiated and regulated is therefore critical to our understanding of both intestinal immunity and chronic inflammatory disease. Our long term goal is to understand how Dendritic Cells (DCs) and other antigen presenting cells initiate and maintain the correct balance of T-helper cell subsets. The objective in this application is to establish how DCs regulate T cell responses to TGF-ß and control Th17 cell differentiation. The rationale for this work is that understanding this process has the potential to translate into new therapies for Th17-mediated diseases. Our central hypothesis is that DC expression of αvß8 and subsequent activation of TGF-ß controls induction and maintenance of Th17 responses. Based on published work and preliminary data, this hypothesis will be tested in three specific aims: (1) Determine how αv integrins expressed by DCs regulate Th17 cell differentiation, particularly the generation of IL17/ IFN-γ-expressing cells associated with autoimmunity. Conditional knockout mice will be used to study the role for αv integrins in vivo, and results will be extended to humans though primary cell culture. (2) Understand how ß8 expression is regulated in DCs during homeostatic regulation and following infection. (3) Determine the mechanisms by which αvß8 function is regulated on DCs using cell biology and biochemical approaches. This approach is innovative as it focuses on the role of DCs in 'licensing' T cell responses to TGF-ß. The proposed work is significant because it will provide a much needed understanding of how DCs promote the initiation of Th17 cells in the intestine and regulate their subsequent differentiation in response to environmental and infectious challenges.
描述(申请人提供):肠上皮等粘膜表面对免疫系统构成了复杂的挑战,因为它们必须保持有效的免疫力,以抵御潜在的病原体攻击,同时还必须耐受共生微生物和饮食抗原。耐受和免疫之间的平衡在很大程度上是由特殊的T细胞群、调节性T细胞(Tregs)和Th17细胞调节的。通过对小鼠和人类的研究,这些亚群之间的平衡被严重破坏,导致结肠炎。此外,Th17细胞正在成为许多其他炎症性和自身免疫性疾病的贡献者。因此,了解Th17反应是如何启动和调节的,对于我们理解肠道免疫和慢性炎症性疾病至关重要。我们的长期目标是了解树突状细胞(DC)和其他抗原提呈细胞如何启动和维持T辅助细胞亚群的正确平衡。本应用的目的是确定DC如何调节T细胞对转化生长因子-β的反应,并控制Th17细胞的分化。这项工作的基本原理是,了解这一过程有可能转化为Th17介导的疾病的新疗法。我们的中心假设是,αv?8的DC表达和随后的激活控制着Th17应答的诱导和维持。根据已发表的工作和初步数据,这一假说将在三个具体目标上得到验证:(1)确定DC表达的αv整合素如何调节Th17细胞的分化,特别是表达IL17/干扰素-γ的细胞的产生 与自身免疫有关。条件基因敲除小鼠将被用来研究αv整合素在体内的作用,结果将通过原代细胞培养扩展到人类。(2)了解在动态平衡调节过程中和感染后,DCs中?8的表达是如何调节的。(3)用细胞生物学和生物化学方法确定αv?8对DC功能的调控机制。这种方法是创新的,因为它侧重于树突状细胞在T细胞应答中的作用 转化生长因子。这项拟议的工作意义重大,因为它将提供迫切需要的理解,了解DC如何促进肠道Th17细胞的启动,并调节它们随后的分化,以应对环境和感染挑战。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Integrin αv in the mechanical response of osteoblast lineage cells.
αv Integrins regulate germinal center B cell responses through noncanonical autophagy.
αv 整合素通过非典型自噬调节生发中心 B 细胞反应。
  • DOI:
    10.1172/jci99597
  • 发表时间:
    2018
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Raso,Fiona;Sagadiev,Sara;Du,Samuel;Gage,Emily;Arkatkar,Tanvi;Metzler,Genita;Stuart,LyndaM;Orr,MarkT;Rawlings,DavidJ;Jackson,ShaunW;Lacy-Hulbert,Adam;Acharya,Mridu
  • 通讯作者:
    Acharya,Mridu
β8 Integrin Expression and Activation of TGF-β by Intestinal Dendritic Cells Are Determined by Both Tissue Microenvironment and Cell Lineage.
  • DOI:
    10.4049/jimmunol.1600244
  • 发表时间:
    2016-09-01
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Boucard-Jourdin M;Kugler D;Endale Ahanda ML;This S;De Calisto J;Zhang A;Mora JR;Stuart LM;Savill J;Lacy-Hulbert A;Paidassi H
  • 通讯作者:
    Paidassi H
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Adam Lacy-Hulbert其他文献

Adam Lacy-Hulbert的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Adam Lacy-Hulbert', 18)}}的其他基金

LITAF regulation of cell death and inflammatory responses
LITAF 调节细胞死亡和炎症反应
  • 批准号:
    10886166
  • 财政年份:
    2023
  • 资助金额:
    $ 37.19万
  • 项目类别:
Immune Signatures and Clinical Outcomes in Acute Pancreatitis
急性胰腺炎的免疫特征和临床结果
  • 批准号:
    10568011
  • 财政年份:
    2023
  • 资助金额:
    $ 37.19万
  • 项目类别:
alpha v integrin regulation of B cell tolerance
B 细胞耐受的 α v 整合素调节
  • 批准号:
    10294130
  • 财政年份:
    2020
  • 资助金额:
    $ 37.19万
  • 项目类别:
Identification of Host Drug Development Targets in Influenza Using Transposon Mutagenesis
使用转座子诱变鉴定流感宿主药物开发靶点
  • 批准号:
    8956296
  • 财政年份:
    2015
  • 资助金额:
    $ 37.19万
  • 项目类别:
Identification of Host Drug Development Targets in Influenza Using Transposon Mutagenesis
使用转座子诱变鉴定流感宿主药物开发靶点
  • 批准号:
    9089858
  • 财政年份:
    2015
  • 资助金额:
    $ 37.19万
  • 项目类别:
Transposon Mutagenesis for Host-Target and Drug Discovery in Infectious Disease
传染病宿主靶标和药物发现的转座子诱变
  • 批准号:
    8883359
  • 财政年份:
    2014
  • 资助金额:
    $ 37.19万
  • 项目类别:
Transposon Mutagenesis for Host-Target and Drug Discovery in Infectious Disease
传染病宿主靶标和药物发现的转座子诱变
  • 批准号:
    8490300
  • 财政年份:
    2012
  • 资助金额:
    $ 37.19万
  • 项目类别:
Dendritic Cell Control of Intestinal T Cell Responses
树突状细胞控制肠道 T 细胞反应
  • 批准号:
    8372489
  • 财政年份:
    2012
  • 资助金额:
    $ 37.19万
  • 项目类别:
Transposon Mutagenesis for Host-Target and Drug Discovery in Infectious Disease
传染病宿主靶标和药物发现的转座子诱变
  • 批准号:
    8391403
  • 财政年份:
    2012
  • 资助金额:
    $ 37.19万
  • 项目类别:
Dendritic Cell Control of Intestinal T Cell Responses
树突状细胞控制肠道 T 细胞反应
  • 批准号:
    8843114
  • 财政年份:
    2012
  • 资助金额:
    $ 37.19万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.19万
  • 项目类别:
    Research Grant
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 37.19万
  • 项目类别:
    Operating Grants
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 37.19万
  • 项目类别:
    Small Business Research Initiative
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 37.19万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 37.19万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 37.19万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 37.19万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 37.19万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 37.19万
  • 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 37.19万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了